Published in Prog Clin Biol Res on January 01, 1984
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA (1996) 3.50
Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science (1986) 3.31
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet (1993) 3.03
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Caffeine consumption. Food Chem Toxicol (1996) 2.84
Molecular pathology of haemophilia B. EMBO J (1989) 2.74
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Natural history of HIV-1 cell-free viremia. JAMA (1995) 2.58
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 2.29
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA (1969) 2.26
Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. Ann Intern Med (1987) 2.24
Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U S A (1990) 2.23
Single nucleotide primer extension to detect genetic diseases: experimental application to hemophilia B (factor IX) and cystic fibrosis genes. Proc Natl Acad Sci U S A (1991) 2.21
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost (1998) 2.20
Hypercoagulability in venous and arterial thrombosis. Ann Intern Med (1997) 2.17
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh (1975) 2.10
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med (1990) 2.05
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Thromboembolic disease--critical evaluation of laboratory investigation. Thromb Haemost (1992) 1.93
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. Am J Hematol (1993) 1.92
Fibrinolytic activity of human veins. Lancet (1967) 1.91
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol (1999) 1.88
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Antibody to human T-lymphotropic virus type III in wives of hemophiliacs. Evidence for heterosexual transmission. Ann Intern Med (1985) 1.82
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
AHF related protein in clinical praxis. Scand J Haematol (1974) 1.78
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis. Acta Chir Scand (1972) 1.74
Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost (2004) 1.72
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
The incidence and distribution of CpG----TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res (1990) 1.64
Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) (1980) 1.64
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 1.61
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res (1980) 1.59
Results from a lifestyle survey: Trent health. Health Educ Res (1994) 1.57
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145. Proc Natl Acad Sci U S A (1983) 1.57
Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost (2007) 1.56
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet (1990) 1.53
Central nervous system bleeding in hemophiliacs. Blood (1978) 1.51
Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Med Scand (1975) 1.51
A nascent secretory protein may traverse the ribosome/endoplasmic reticulum translocase complex as an extended chain. J Biol Chem (1996) 1.51
Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med (1988) 1.51
Development and early natural history of HTLV-III antibodies in persons with hemophilia. JAMA (1985) 1.50
Silent infections with human immunodeficiency virus type 1 are highly unlikely in multitransfused seronegative hemophiliacs. Blood (1990) 1.49
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Determination of plasminogen in clots and thrombi. Thromb Diath Haemorrh (1966) 1.48
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynecol Scand (1967) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Thrombin generation in vascular tissue. J Thromb Haemost (2006) 1.47
A psychosocial needs assessment of patients with homozygous beta-thalassemia. Ann N Y Acad Sci (1985) 1.46
Haemophilia prophylaxis in Sweden. Acta Paediatr Scand (1976) 1.46
Rare coagulation disorders. Thromb Haemost (1999) 1.46
Vitamin K and the newborn. N Engl J Med (1993) 1.45
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med (1997) 1.44
Heterosexual transmission of human immunodeficiency virus: association with severe depletion of T-helper lymphocytes in men with hemophilia. AIDS Res Hum Retroviruses (1987) 1.44
Intravascular coagulation and acute renal failure in a child with mycoplasma infection. Acta Med Scand (1971) 1.44
Hepatitis and clotting-factor concentrates. JAMA (1972) 1.44
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol (1984) 1.43
A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost (1996) 1.43